Comparative Pharmacology
Head-to-head clinical analysis: METRONIDAZOLE versus SOLOSEC.
Head-to-head clinical analysis: METRONIDAZOLE versus SOLOSEC.
METRONIDAZOLE vs SOLOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.
Secnidazole is a nitroimidazole antibiotic that exerts its bactericidal activity by entering the bacterial cell and inhibiting DNA synthesis. The nitro group of secnidazole is reduced intracellularly to form free radicals and other reactive intermediates that damage bacterial DNA.
500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.
2 g orally as a single dose for trichomoniasis.
None Documented
None Documented
Clinical Note
moderateMetronidazole + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Metronidazole."
Clinical Note
moderateMetronidazole + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Metronidazole."
Clinical Note
moderateMetronidazole + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Metronidazole."
Clinical Note
moderateMetronidazole + Clotrimazole
8 hours (range 6-10 hours) in adults; prolonged to 18-20 hours in severe hepatic impairment; requires adjustment in cirrhosis.
Terminal elimination half-life approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment
Renal (60-80% unchanged drug), biliary/fecal (6-15% as metabolites, <20% unchanged).
Renal: approximately 75% as unchanged drug; fecal/biliary: minor (estimated <10%)
Category A/B
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic
"The metabolism of Clotrimazole can be decreased when combined with Metronidazole."